Amylx Pharmaceuticals Inc vs Occidental Petroleum Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Occidental Petroleum Corporation trades at $59.01 (market cap $55.89B). The key difference: Occidental Petroleum Corporation is far larger — about 22.1× Amylx Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 2% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | OXY | |
|---|---|---|
Market Cap | $2.53B | $55.89B |
Sector | Health | Energy |
52-Week High | $24.19 | $66.24 |
52-Week Low | $7.82 | $38.92 |
Enterprise Value | $2.28B | $74.65B |
Dividend Yield | — | 2% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Occidental Petroleum (OXY) trades at $55.91, down 0.23% today, with a bullish technical outlook supported by moving averages and a consensus price target of $69.25. Recent Q2 2026 earnings of $2.40 per share beat expectations, driven by higher oil prices and strong cash flow, while the company focuses on debt reduction and targets over $4 billion in sustainable cash flow by 2030.
OXY presents a buy opportunity with solid profitability and growth prospects, but faces risks from oil price volatility and competitive pressures. Analysts are optimistic, with 50% recommending buy, though investors should monitor execution on cash flow targets and energy market fluctuations.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →